ADVM241220C20000
- 0.95
- 0.000.00%
Adverum Biotechnologies Newsroom
Mizuho Securities Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating, Cuts Target Price to $16
Mizuho Securities Cuts Price Target on Adverum Biotechnologies to $16 From $20, Outperform Rating Maintained
Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Express News | Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Truist Financial Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating
H.C. Wainwright Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating, Maintains Target Price $30
Adverum Biotechnologies Advances Ixo-vec Gene Therapy Trials
Buy Rating on Adverum Biotechnologies: Ixo-vec's Promising Potential in Transforming Wet AMD Treatment
Adverum Reports Positive Ixo-vec Data for Wet Age-Related Macular Degeneration; Shares Rise Pre-Bell
Express News | Adverum Biotechnologies Inc: 6E10 Dose in Luna Maintains Visual and Anatomic Endpoints
Express News | Adverum Biotechnologies Inc: Expects to Be Able to Fund Operations Into Second Half of 2025
Adverum Biotechnologies Announces Positive 52-Week LUNA and 4-Year OPTIC Results, and Provides Key Pivotal Program Design Elements
Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements
Adverum Biotechnologies Is Maintained at Sector Perform by RBC Capital
Adverum Biotechnologies Analyst Ratings
RBC Capital Initiates Adverum Biotechnologies(ADVM.US) With Hold Rating, Announces Target Price $10
TD Cowen Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating
A Quick Look at Today's Ratings for Adverum Biotechnologies(ADVM.US), With a Forecast Between $10 to $30
Buy Rating on Adverum Biotechnologies Driven by Ixo-vec's Promising Data and Potential Impact on AMD Treatment
Express News | Adverum Biotechnologies Inc : RBC Cuts Target Price to $10 From $12